In Phase 2 trials, retatrutide's highest dose group (12 mg) produced a mean body weight reduction of 24.2% at 48 weeks, compared to approximately 22.5% for tirzepatide's highest dose in its own trials
Why Traditional Solutions May Fall Short Many patients assume that standard facial rejuvenation approaches will adequately address GLP-1-related changes
Physiol Rev 103 (2), 11371191
May your receptors stay responsive, your protocols stay optimized, and your results stay consistent.
Now, a new study published in the journal For this study, researchers analyzed blood and joint fluid samples from participants of the Inflammation in Arthritis (INART) biobank at Aarhus University Hospital in Denmark
Headache: Occasional, typically transient